News und Analysen
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that it
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
Regulatory News:
NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
DGAP-News: Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022
Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting
Transgene’s Combined General Meeting of May 25, 2022
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400
Nicox (COX): Eye health portfolio targets large markets
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
This replaces the announcement made at 4:40PM EDT/20:40 CEST on May 18 due to the following correction: Updated date in "First Quarter Operational Highlights" section.
NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
DGAP-News: ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the "Company"), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for